

## Meeting of steering committee Agenda\* for 2 March 2021

## (\*this agenda is attachment 1 in the meeting package)

0. Review action items from last meeting and today's agenda	0		
TANDING ITEMS     Topic (change to 'Notes and actions' in action items doc)			
A) Activity streams			
1. New or updated syntheses			
• Intake and prioritization (includes intake for living docs)	<ul> <li><u>8 requests to date</u>:</li> <li>1) vaccine roll-out - accepted, completed LEP 1.1, 1.2, 1.3, 1.4</li> <li>2) drug treatments - responded with referrals (response 2)</li> <li>3) vaccination in asymptomatic LTC residents - accepted, completed REP 25</li> <li>4) vaccine effects on transmission - responded with status of existing living evidence syntheses (response 2); see request #6 for additional work</li> <li>5) viral transmission among vaccinated people – accepted, LES in progress</li> <li>6) factors affecting health workers' attitudes towards vaccination uptake and strategies – responded with referrals (response 6)</li> <li>7) variants of concern and their implications – accepted, LES in progress</li> <li>8) crisis management and renewal in long-term care – accepted, LEP 2.1</li> </ul>		
• Rapid evidence profiles (REPs)	See above		
<ul> <li>Rapid evidence profiles (RLA 3)</li> <li>Rapid evidence syntheses (RSs)</li> </ul>	See above     See above		
<ul> <li>Plain language summaries (includes summaries for living documents below)</li> </ul>	Process document completed; template completed; currently being tested		
2. Living evidence syntheses			
• Living evidence profiles (LEP)	• See above		
• Living evidence syntheses (LES)	See above		
• Other	Living behavioural sciences document to support vaccine uptake		
3. Inventory of 'best evidence synt	heses'		
• Status	<ul> <li>Note greater visibility to four sections and new introductions to each</li> <li>Reduction in noise-to-signal ratio: 5,440 syntheses from high-quality / high-yield sources → 4,188 non-duplicate syntheses → 2,731 decision-relevant syntheses → 339 'best' evidence syntheses</li> </ul>		
Searchable database	•		
• Inventory spotlights	<ul> <li>Canadian and global and domestic spotlights posted on website and disseminated</li> <li><u>Canadian spotlights</u> (1, 2.1, 2.2) – note two rapid syntheses about ivermectin despite living evidence syntheses</li> <li><u>Global spotlights</u> (1, 2.1, 2.2)</li> <li><u>Subscription model</u> implemented: twice-a-month 'newsletter' to keep current with three types of products: 1) Canadian spotlights; 2) global spotlights; and 3) horizon scans <u>see current issue here: second half of February 2021</u></li> </ul>	5 min	
4. Evidence-demand coordination			
• Canadian Public Health Network (SAC and TAC)	Update on plan for SAC presentation	1 min	
• Other PHAC (Chief Science Officer, CPTG)	See below (and attachment		
Other federal government	• Review revised list of federal contacts - see attachment 3	5 min	

<ul> <li>Provincial and territorial</li> </ul>	Review revised list of territorial contacts (same attachment 3) and		
governments	brainstorm about NWT contacts		
Tracking	See action 1 above		
• Webinars (and presentations)	<ul> <li>Two webinars completed, one being planned:         <ul> <li>By-invitation webinar: training for evidence-synthesis teams, 16 February 2021</li> <li>Public webinar public: citizen engagement in evidence synthesis, 23 February 2021</li> <li>March (date TBD) (by-invitation) training for citizen partners group</li> </ul> </li> </ul>		
5.Horizon scanning			
Adjustments to existing process	•		
Canadian panel membership	• Eight members confirmed, recruitment underway - see attachment 4		
6.Evidence-supply coordination			
Evidence-synthesis teams	Planning for quarterly meeting	1 min	
<ul> <li>Canadian synthesis spotlights</li> </ul>	• See section 3		
Dissemination vehicles	• Dissemination plan completed, and two rounds of communication completed		
B) Cross-cutting			
1. Citizen partnership	<ul> <li>Planning completed</li> <li>Recruitment underway: formally launched 23 February, deadline to apply is 12 March 2021</li> <li>Training program being developed for citizen partners' participation in evidence syntheses</li> </ul>	5 min	
2. Indigenous peoples engagement	•		
<b>3.</b> Website and communications	Website overhaul completed - see <u>Resources for Canadians</u> (as well as global sections of website)		
4. Measuring impact	•		
OTHER BUSINESS / ARISING	SISSUES		
1. Round table: relevant initiatives	Brief updates about other relevant initiatives underway in Canada		
2. Upcoming meetings	<ul> <li>Collaborators meeting 1 April 12 pm EST</li> <li>Next meeting of Steering Committee: provisionally booked for 18 May, and then entering every two months recurrence</li> </ul>		
3. Other business	Other business - TBD	5 min	



## Steering committee members

Role category	Name	Role	Organization	Email
Representatives of evidence- synthesis teams based in government	Trevor Corneil	Senior Medial Advisor, COVID-19 Pandemic Response, Government of BC	BC CDC and Ministry of Health	trevor.corneil@ubc.ca
	Anne Hayes	Director, Research, Analysis and Evaluation Branch (RAEB)	Ontario Ministry of Health	anne.hayes@ontario.ca
	<b>Andrea Proctor</b> (delegate for Anne)	Manager, Evidence Synthesis Unit, RAEB	Ontario Ministry of Health	andrea.proctor@ontario.ca
	Denis Roy	Vice-président, Stratégie, Institut national d'excellence en santé et en services sociaux	INESSSS	denis.roy@inesss.qc.ca
Representatives of KT/ intermediary initiatives	Maureen Dobbins	Scientific Director	National Collaborating Centres for Methods and Tools (NCCMT)	dobbinsm@mcmaster.ca
	Margo Greenwood	Academic Leader	National Collaborating Centre for Indigenous Health	margo.greenwood@unbc.ca
Citizen leaders	Maureen Smith	Chair	Cochrane Consumer Network Executive	maureen smith@rogers.com
	One other person			
Representatives of major	Doris Grinspun	Chief Executive Officer	Registered Nurses' Association of Ontario	dgrinspun@rnao.ca
professional bodies	Owen Adams	Senior Advisor to the CEO	Canadian Medical Association	owen.adams@cma.ca
Representatives of policymakers/ leaders	Marina Salvadori	Senior Medical Advisor, Clinical Lead COVID-19	Public Health Agency of Canada	<u>marina.salvadori@canada.ca</u>
	Braden Manns	Associate Chief Medical Officer	Alberta Health Services	<u>braden.manns@albertahealthse</u> <u>rvices.ca</u>
	Gaynor Watson-Creed	Deputy Chief Medical Officer of Health, Nova Scotia Health Authority	Nova Scotia Department of Health and Wellness	<u>gaynor.watson-</u> <u>creed@novascotia.ca</u>
Co-principal applicants	John Lavis	Co-Lead, COVID-END and Director, McMaster Health Forum	COVID-END, McMaster Health Forum   RISE	<u>lavisj@mcmaster.ca</u>
	Andrea Tricco	Director, Knowledge Synthesis Team in the Knowledge Translation Program, Li Ka Shing Knowledge Institute of St. Michael's Hospital	SPOR-EA	andrea.tricco@unityhealth.to
	Nancy Santesso	Deputy Director	Cochrane Canada	santesna@mcmaster.ca
	Jeremy Grimshaw	Co-Lead, COVID-END, and Senior Scientist, Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI)	COVID-END, OHRI   RISE	jgrimshaw@ohri.ca
Ex-officio members	Alfonso Iorio	Chair, Department of Health Research Methods, Evidence & Impact and Director, Health Information Research Unit	COVID+, McMaster University	iorioa@mcmaster.ca
	Ileana Ciurea	Senior Advisor, Strategy, Collaborations and Innovation	COVID-END, McMaster Health Forum   RISE	<u>ciurea@mcmaster.ca</u>
Staff support and note-taker	Sara Weberman	Senior Project Manager	COVID-END, McMaster Health Forum   RISE	webermsm@mcmaster.ca